



STRATEGIC PARTNER:



AGENDA FOR THE ACCELERATE ANNUAL CONFERENCE

Shifting Gears in Paediatric Cancer Innovation

**5-6 FEB
2026**

**Brussels
& Online**

HEADLINE
CONFERENCE
SUPPORTER:



'THE DUAL ENGINE APPROACH'

To cure more children and adolescents with cancer, we must both accelerate the smart development and use of adult cancer innovations and build new paediatric-first development pathways to incentivize the development of specific paediatric oncology drugs.

DAY 1: 5th FEB

09:00 - 10:00	Welcome Coffee
10:00 - 10:20	Introduction <ul style="list-style-type: none">• Vision and Mission of ACCELERATE - Nicole Scobie, ACCELERATE• Goals of the Conference - The Thread - "Dual engine approach" - Gilles Vassal, ACCELERATE
10:20 - 11:00	ACKNOWLEDGING TODAY'S REALITY Understanding the global framework for paediatric oncology drug development for the next 5 years <ul style="list-style-type: none">• Global Oncology trends - Murray Aitken, IQVIA Institute of Human Data Science; LSE (USA)• Discussion: What would be the impact on pediatric cancer research and drug development?
11:10 - 12:30	Session I - Improving generation of evidence in paediatric oncology drug development <ul style="list-style-type: none">• Use of Real Word Data: SACHA International - Pablo Berlanga, Gustave Roussy (France)• Advancing Childhood Cancer Academic-Industry Collaborative Platform - Pamela Kearns, University of Birmingham (UK)• ACCELERATE Working group on Patient Reported Outcomes – Franziska Helmberg, Medical University Innsbruck (Germany)• Panel Discussion
12:30 - 1:30	Lunch Advocates networking (closed session)
1:30 - 3:30	CALLING FOR A SHIFT Session II - Accelerating the development of specific paediatric oncology products <ul style="list-style-type: none">• Learning from the development of antiGD2 antibodies for the treatment of neuroblastoma: an academic perspective - Steven DuBois, Dana-Farber Cancer Institute (USA)• Development of Cuprion™ for the treatment of Wilson disease - Omar Camille Kamlin, Orphalan (France)

- Generating scientific evidence for specific paediatric drug development - The ITCC-LifeArc project - Jan Molenaar, Princess Maxima Center for Paediatric Oncology (*The Netherlands*)
- New European initiatives : Biotech Act, European Innovation Act - Vlad Olteanu, *Europabio (BE)*
- Panel discussion

3:30 - 4:00 **Coffee break + group photo**

Paediatric Strategy and Impact Forums

4:00 - 4:45

- Results of the Paediatric Strategy Forum on Antibody Drug - *Margaret Macy, Children's Hospital Colorado (USA)*
- Presentation of the 2026 Paediatric Strategy Forum – *Pablo Berlanga, Gustave Roussy (France)*
- Plan for future Forums and workshop – *Elizabeth Fox, St Jude Children's Research Hospital (USA)*

Break-out sessions (on site and by zoom)

4:45 - 6:30

- **Topic 1:** Accelerating paediatric development of adult innovations: how do we get early conduct of studies leading to regulatory approvals?
- **Topic 2:** Developing specific paediatric oncology drugs: what are the gaps in knowledge, barriers and constraints? What are the drivers to get paediatric oncology in Start-up and Biotech companies?

6:30 **End of day 1**

DAY 2: 6th FEB

CHALLENGING THE SYSTEM

Session III - Will the regulatory framework support and incentivize?

8:30 - 10:30

- Update on regulatory changes for paediatric development of adult anticancer drugs in Europe - *Dominik Karres, European Medicines Agency (The Netherlands)*
- Update on regulatory changes for paediatric development of adult anticancer drugs in North America - *Martha Donoghue, Food and Drug Administration, (USA)*
- Changes in the Declaration of Helsinki for vulnerable populations: a paradigm change - *Rieke van der Graaf, MedEthicsEU (The Netherlands)*
- Panel discussion: What role for ACCELERATE in the changing regulatory environment?

4:45 - 6:30 **Coffee break**

DRIVING TO ACTION

Session IV - Accelerating drug paediatric development of adult innovations

- Access to drug for investigator supported trials - Brenda Weigel, St Jude Children's Research Hospital (USA)
- Cross border access to therapeutic innovations in Europe - Francisco Bautista Sirvent, Princess Maxima Centrum (The Netherlands)
- Facilitating access to clinical trials in Canada - Daniel Morgenstern, Hospital for Sick Children (Canada)
- **Report from Break Out Session topic 1 and proposing a plan**
Accelerating paediatric development of adult innovations: how do we get early conduct of studies leading to regulatory approvals?

11:00 - 1:00

Lunch

Charity Partners of ACCELERATE networking (closed session)

1:00 - 2:00

Session V - Developing paediatric-specific oncology drugs

- Igniting Childhood Cancer Gene Therapy - Aleck Jones, Kindling Bio (UK)
Presentation by a biotech - (TBC)
- **Report from Break Out Session topic 2**
Developing specific paediatric oncology drugs: what are the gaps in knowledge, barriers and constraints? What are the drivers to get paediatric oncology in Start-up and Biotech companies?

2:00 - 3:30

Session VI - Building the ACCELERATE work plan

Chairs: Nicole Scobie and Gilles Vassal, ACCELERATE

3:30 - 4:15

Wrap up

4:15 - 4:30

End of day 2

WE GRATEFULLY ACKNOWLEDGE THE GENEROUS SUPPORT OF OUR ACCELERATE PARTNERS:

